Update on the detection and treatment of atherogenic low-density lipoproteins

Allan Sniderman, Peter O. Kwiterovich

Research output: Contribution to journalArticle

Abstract

Purpose of Review: To explain why epidemiological studies have reached such diverse views as to whether apolipoprotein B (apoB) and/or low-density lipoprotein particle number (LDL-P) are more accurate markers of the risk of cardiovascular disease than LDL-C or non-high-density lipoprotein cholesterol (HDL-C) and to review the treatment options to lower LDL. Recent Findings: The Emerging Risk Factor Collaboration, a large prospective participant level analysis, a meta-analysis of statin clinical trials, and the Heart Protection Study have each reported that apoB does not add significantly to the cholesterol markers as indices of cardiovascular risk. By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C. As well, three studies using discordance analysis each demonstrated that apoB and LDL-P were superior to the cholesterol markers. Two approaches to resolve these differences are brought to bear in this article: first, which results are credible and second, how does taking the known differences in LDL composition into account, help resolve them. The best identification of individuals at risk of coronary artery disease or with coronary artery disease allows the most efficacious treatment of elevated LDL-P and will permit a more extensive use of some of the more novel LDL-lowering agents. Summary: Much of the controversy vanishes once the physiologically driven differences in the composition of the apoB lipoprotein particles are taken into account, illustrating that epidemiology, not directed by physiology, is like shooting without aiming.

Original languageEnglish (US)
Pages (from-to)140-147
Number of pages8
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume20
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Apolipoproteins B
LDL Lipoproteins
Meta-Analysis
Coronary Artery Disease
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
Epidemiologic Studies
Epidemiology
Cardiovascular Diseases
Clinical Trials
Prospective Studies
oxidized low density lipoprotein
lipoprotein cholesterol

Keywords

  • Apolipoprotein B
  • Cardiovascular risk
  • Low-density lipoprotein cholesterol
  • Low-density lipoprotein particle number
  • Nonhigh-density lipoprotein cholesterol

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Update on the detection and treatment of atherogenic low-density lipoproteins. / Sniderman, Allan; Kwiterovich, Peter O.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 20, No. 2, 04.2013, p. 140-147.

Research output: Contribution to journalArticle

@article{fb9536407ac54071b0e81edf39f3b245,
title = "Update on the detection and treatment of atherogenic low-density lipoproteins",
abstract = "Purpose of Review: To explain why epidemiological studies have reached such diverse views as to whether apolipoprotein B (apoB) and/or low-density lipoprotein particle number (LDL-P) are more accurate markers of the risk of cardiovascular disease than LDL-C or non-high-density lipoprotein cholesterol (HDL-C) and to review the treatment options to lower LDL. Recent Findings: The Emerging Risk Factor Collaboration, a large prospective participant level analysis, a meta-analysis of statin clinical trials, and the Heart Protection Study have each reported that apoB does not add significantly to the cholesterol markers as indices of cardiovascular risk. By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C. As well, three studies using discordance analysis each demonstrated that apoB and LDL-P were superior to the cholesterol markers. Two approaches to resolve these differences are brought to bear in this article: first, which results are credible and second, how does taking the known differences in LDL composition into account, help resolve them. The best identification of individuals at risk of coronary artery disease or with coronary artery disease allows the most efficacious treatment of elevated LDL-P and will permit a more extensive use of some of the more novel LDL-lowering agents. Summary: Much of the controversy vanishes once the physiologically driven differences in the composition of the apoB lipoprotein particles are taken into account, illustrating that epidemiology, not directed by physiology, is like shooting without aiming.",
keywords = "Apolipoprotein B, Cardiovascular risk, Low-density lipoprotein cholesterol, Low-density lipoprotein particle number, Nonhigh-density lipoprotein cholesterol",
author = "Allan Sniderman and Kwiterovich, {Peter O.}",
year = "2013",
month = "4",
doi = "10.1097/MED.0b013e32835ed9cb",
language = "English (US)",
volume = "20",
pages = "140--147",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Update on the detection and treatment of atherogenic low-density lipoproteins

AU - Sniderman, Allan

AU - Kwiterovich, Peter O.

PY - 2013/4

Y1 - 2013/4

N2 - Purpose of Review: To explain why epidemiological studies have reached such diverse views as to whether apolipoprotein B (apoB) and/or low-density lipoprotein particle number (LDL-P) are more accurate markers of the risk of cardiovascular disease than LDL-C or non-high-density lipoprotein cholesterol (HDL-C) and to review the treatment options to lower LDL. Recent Findings: The Emerging Risk Factor Collaboration, a large prospective participant level analysis, a meta-analysis of statin clinical trials, and the Heart Protection Study have each reported that apoB does not add significantly to the cholesterol markers as indices of cardiovascular risk. By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C. As well, three studies using discordance analysis each demonstrated that apoB and LDL-P were superior to the cholesterol markers. Two approaches to resolve these differences are brought to bear in this article: first, which results are credible and second, how does taking the known differences in LDL composition into account, help resolve them. The best identification of individuals at risk of coronary artery disease or with coronary artery disease allows the most efficacious treatment of elevated LDL-P and will permit a more extensive use of some of the more novel LDL-lowering agents. Summary: Much of the controversy vanishes once the physiologically driven differences in the composition of the apoB lipoprotein particles are taken into account, illustrating that epidemiology, not directed by physiology, is like shooting without aiming.

AB - Purpose of Review: To explain why epidemiological studies have reached such diverse views as to whether apolipoprotein B (apoB) and/or low-density lipoprotein particle number (LDL-P) are more accurate markers of the risk of cardiovascular disease than LDL-C or non-high-density lipoprotein cholesterol (HDL-C) and to review the treatment options to lower LDL. Recent Findings: The Emerging Risk Factor Collaboration, a large prospective participant level analysis, a meta-analysis of statin clinical trials, and the Heart Protection Study have each reported that apoB does not add significantly to the cholesterol markers as indices of cardiovascular risk. By contrast, a meta-analysis of published prospective studies demonstrated that non-HDL-C was superior to LDL-C, and apoB was superior to non-HDL-C. As well, three studies using discordance analysis each demonstrated that apoB and LDL-P were superior to the cholesterol markers. Two approaches to resolve these differences are brought to bear in this article: first, which results are credible and second, how does taking the known differences in LDL composition into account, help resolve them. The best identification of individuals at risk of coronary artery disease or with coronary artery disease allows the most efficacious treatment of elevated LDL-P and will permit a more extensive use of some of the more novel LDL-lowering agents. Summary: Much of the controversy vanishes once the physiologically driven differences in the composition of the apoB lipoprotein particles are taken into account, illustrating that epidemiology, not directed by physiology, is like shooting without aiming.

KW - Apolipoprotein B

KW - Cardiovascular risk

KW - Low-density lipoprotein cholesterol

KW - Low-density lipoprotein particle number

KW - Nonhigh-density lipoprotein cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84874949110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874949110&partnerID=8YFLogxK

U2 - 10.1097/MED.0b013e32835ed9cb

DO - 10.1097/MED.0b013e32835ed9cb

M3 - Article

C2 - 23422241

AN - SCOPUS:84874949110

VL - 20

SP - 140

EP - 147

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 2

ER -